

# Sjoerd T T Schetters

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8420954/publications.pdf>

Version: 2024-02-01

27  
papers

2,025  
citations

840585

11  
h-index

713332

21  
g-index

29  
all docs

29  
docs citations

29  
times ranked

4196  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology. <i>Brain</i> , 2016, 139, 891-907.	3.7	389
2	The tumour glyco-code as a novel immune checkpoint for immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 204-211.	10.6	303
3	The PD-1/PD-L1-Checkpoint Restrains T Cell Immunity in Tumor-Draining Lymph Nodes. <i>Cancer Cell</i> , 2020, 38, 685-700.e8.	7.7	299
4	Neuroinflammation: Microglia and T Cells Get Ready to Tango. <i>Frontiers in Immunology</i> , 2017, 8, 1905.	2.2	257
5	Transcriptional profiling of CD11c-positive microglia accumulating around amyloid plaques in a mouse model for Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 1847-1860.	1.8	158
6	Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 3329-3334.	3.3	135
7	Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. <i>Nature Communications</i> , 2021, 12, 1270.	5.8	111
8	Functional CD169 on Macrophages Mediates Interaction with Dendritic Cells for CD8+ T Cell Cross-Priming. <i>Cell Reports</i> , 2018, 22, 1484-1495.	2.9	106
9	Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8+ T cells. <i>Acta Biomaterialia</i> , 2019, 91, 248-257.	4.1	76
10	Differential role of CCR2 in the dynamics of microglia and perivascular macrophages during prion disease. <i>Glia</i> , 2014, 62, 1041-1052.	2.5	44
11	Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy. , 2020, 8, e000588.		38
12	Mouse DC-SIGN/CD209a as Target for Antigen Delivery and Adaptive Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 990.	2.2	35
13	Immunological dynamics after subcutaneous immunization with a squalene-based oil-in-water adjuvant. <i>FASEB Journal</i> , 2020, 34, 12406-12418.	0.2	11
14	Human CXCR5 <sup>+</sup> PD-1 <sup>+</sup> CD8 T cells in healthy individuals and patients with hematologic malignancies. <i>European Journal of Immunology</i> , 2021, 51, 703-713.	1.6	11
15	Chemically engineered glycan-modified cancer vaccines to mobilize skin dendritic cells. <i>Current Opinion in Chemical Biology</i> , 2019, 53, 167-172.	2.8	9
16	Bacterial inclusion bodies function as vehicles for dendritic cell-mediated T cell responses. <i>Cellular and Molecular Immunology</i> , 2020, 17, 415-417.	4.8	9
17	Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits. <i>Communications Biology</i> , 2022, 5, 41.	2.0	8
18	Adaptable antigen matrix platforms for peptide vaccination strategies and T cell-mediated anti-tumor immunity. <i>Biomaterials</i> , 2020, 262, 120342.	5.7	7

#	ARTICLE	IF	CITATIONS
19	Immune involvement of the contralateral hemisphere in a glioblastoma mouse model. , 2020, 8, e000323.		6
20	Myeloid-Specific Aclý Deletion Alters Macrophage Phenotype In Vitro and In Vivo without Affecting Tumor Growth. Cancers, 2021, 13, 3054.	1.7	6
21	Palmitoylated antigens for the induction of anti-tumor CD8+ TÁcells and enhanced tumor recognition. Molecular Therapy - Oncolytics, 2021, 21, 315-328.	2.0	3
22	Pulmonary Eosinophils at the Center of the Allergic Space-Time Continuum. Frontiers in Immunology, 2021, 12, 772004.	2.2	2
23	EXTH-21. REPURPOSING GLIOBLASTOMA EXOSOMES AS PERSONALIZED MULTI-ANTIGENIC ANTI-TUMOR VACCINE. Neuro-Oncology, 2018, 20, vi89-vi89.	0.6	1
24	Future prospects of translational and clinical eosinophil research. , 2022, , 253-262.		1
25	IMMU-30. HIGH-DIMENSIONAL PHENOTYPING OF IMMUNE SUBSETS AND CHECKPOINTS IN THE MOUSE GLIOBLASTOMA MICROENVIRONMENT. Neuro-Oncology, 2018, 20, vi127-vi127.	0.6	0
26	Singleâ€cell profiling of circulating and brainâ€resident immune cells in a mouse model for amyloidosis and in aged mice. Alzheimer's and Dementia, 2020, 16, e041789.	0.4	0
27	Abstract A110: Efficacy of anti-PD1 immune checkpoint blockade involves the cooperative interaction of myeloid and lymphoid subpopulations in the tumor microenvironment. , 2019, , .		0